Cellectis (NASDAQ:CLLS - Get Free Report) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued to investors on Monday.
Cellectis Stock Up 8.2%
Shares of NASDAQ:CLLS traded up $0.12 during trading hours on Monday, hitting $1.58. The company's stock had a trading volume of 49,716 shares, compared to its average volume of 142,352. Cellectis has a 52 week low of $1.10 and a 52 week high of $3.00. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. The company has a market capitalization of $87.82 million, a price-to-earnings ratio of -1.22 and a beta of 3.11. The firm's fifty day moving average price is $1.39 and its 200 day moving average price is $1.58.
Cellectis (NASDAQ:CLLS - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.03). The firm had revenue of $12.03 million during the quarter, compared to analysts' expectations of $12.71 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. As a group, research analysts expect that Cellectis will post -0.46 EPS for the current year.
Institutional Investors Weigh In On Cellectis
A number of hedge funds have recently modified their holdings of the business. Long Focus Capital Management LLC increased its position in Cellectis by 2.2% during the first quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company's stock worth $5,849,000 after purchasing an additional 100,000 shares during the last quarter. B Group Inc. purchased a new position in Cellectis in the fourth quarter worth approximately $5,547,000. Millennium Management LLC purchased a new position in Cellectis in the fourth quarter worth approximately $962,000. OLD Mission Capital LLC purchased a new stake in shares of Cellectis during the 1st quarter worth approximately $31,000. Finally, Wells Fargo & Company MN lifted its position in shares of Cellectis by 103.4% during the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock worth $44,000 after buying an additional 12,500 shares during the last quarter. 63.90% of the stock is currently owned by institutional investors and hedge funds.
Cellectis Company Profile
(
Get Free Report)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Further Reading
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
